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Abstract
Background: Plasmodium falciparum Merozoite Surface Protein-6 (PfMSP6) is a component of the complex 
proteinacious coat that surrounds P. falciparum merozoites. This location, and the presence of anti-PfMSP6 antibodies in 
P. falciparum-exposed individuals, makes PfMSP6 a potential blood stage vaccine target. However, genetic diversity has 
proven to be a major hurdle for vaccines targeting other blood stage P. falciparum antigens, and few endemic field 
studies assessing PfMSP6 gene diversity have been conducted. This study follows PfMSP6 diversity in the Peruvian 
Amazon from 2003 to 2006 and is the first longitudinal assessment of PfMSP6 sequence dynamics.
Methods: Parasite DNA was extracted from 506 distinct P. falciparum infections spanning the transmission seasons 
from 2003 to 2006 as part of the Malaria Immunology and Genetics in the Amazon (MIGIA) cohort study near Iquitos, 
Peru. PfMSP6 was amplified from each sample using a nested PCR protocol, genotyped for allele class by agarose gel 
electrophoresis, and sequenced to detect diversity. Allele frequencies were analysed using JMP v.8.0.1.0 and correlated 
with clinical and epidemiological data collected as part of the MIGIA project.
Results: Both PfMSP6 allele classes, K1-like and 3D7-like, were detected at the study site, confirming that both are 
globally distributed. Allele frequencies varied significantly between transmission seasons, with 3D7-class alleles 
dominating and K1-class alleles nearly disappearing in 2005 and 2006. There was a significant association between 
allele class and village location (p-value = 0.0008), but no statistically significant association between allele class and 
age, sex, or symptom status. No intra-allele class sequence diversity was detected.
Conclusions: Both PfMSP6 allele classes are globally distributed, and this study shows that allele frequencies can 
fluctuate significantly between communities separated by only a few kilometres, and over time in the same 
community. By contrast, PfMSP6 was highly stable at the sequence level, with no SNPs detected in the 506 samples 
analysed. This limited diversity supports further investigation of PfMSP6 as a blood stage vaccine candidate, with the 
clear caveat that any such vaccine must either contain both alleles or generate cross-protective responses that react 
against both allele classes. Detailed immunoepidemiology studies are needed to establish the viability of these 
approaches before PfMSP6 advances further down the vaccine development pipeline.
Background
The search for an effective Plasmodium falciparum vac-
cine has been the focus for research efforts by numerous
labs over several decades. While the advancement of the
pre-erythrocytic vaccine RTS,S, to Phase III trials raises
hopes that a vaccine providing some protection against
severe malaria could be on the horizon, clear room for
improved efficacy remains even within the context of
RTS,S [1], making P. falciparum vaccine development an
ongoing and urgent priority. However, P. falciparum pres-
ents an overwhelming number of potential vaccine tar-
gets, both because its complex life cycle presents several
potential stages to target and because the size of the
genome presents multiple potential targets at each stage
[2]. Given the finite resources available, it is not feasible
for every antigen to advance to vaccine trials; there is,
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therefore, an urgent need for a more rational approach to
candidate selection. Such concerns are highlighted by the
collaborative Malaria Vaccine Technology Roadmap [3],
which proposes that all potential candidates progressing
through the vaccine development pipeline be subjected to
strict go/no-go criteria; similar issues have been dis-
cussed in detail in recent reviews [4,5]. The acquisition of
field data describing vaccine candidate sequence diversity
and antigenicity in various transmission environments is
one key component of these pipeline checkpoints.
Plasmodium falciparum Merozoite Surface Protein-6
(PfMSP6) is a potential vaccine candidate at an early stage
in development, which still lacks critical field data to
inform the go/no-go decisions necessary to either
advance it down the pipeline or remove it from consider-
ation. PfMSP6 is a secreted antigen that is proteolytically
processed by PfSUB1 into a 36 kDa fragment that associ-
ates with fragments of PfMSP1 and PfMSP7 to form a
multi-subunit complex on the merozoite surface [6-8].
PfMSP6 is encoded by one gene in a multi-gene family
arranged in close proximity along chromosome 10 [9]. All
members of this multi-gene family appear to encode
merozoite surface antigens, one of which, PfMSP3, has
already advanced to several Phase I vaccine trials [10-12].
Although the function of PfMSP6 remains unknown, it
has been postulated to participate in erythrocyte recogni-
tion and binding, as have many other merozoite surface
proteins of unknown functions. PfMSP6 is, therefore, in
the right place to be a theoretical vaccine candidate, and
its potential is supported by field studies that have
observed anti-PfMSP6 antibody responses in serum from
P. falciparum-infected individuals, which inhibit P. falci-
parum  growth  in vitro [13,14]. However, like many
potential vaccine antigens, few detailed genetic or immu-
noepidemiology studies have been carried out in endemic
settings.
Recent studies of two of the most advanced blood stage
candidates, PfMSP1 and PfAMA1, have made it clear that
sequence diversity is a major hurdle for blood stage vac-
cines [15], and PfMSP6 is no exception. Past studies of
PfMSP6 have shown that like other major merozoite sur-
face antigens PfMSP1 and PfMSP2 [16], it is dimorphic.
The two major PfMSP6 allele classes are referred to as
K1- and 3D7-like alleles, named for the strains in which
they were first identified [17]. Differences between the
alleles are largely restricted to a series of indels in the N-
terminal domain, but also include single nucleotide poly-
morphisms (SNPs) within each allele class that are found
in both the N-terminal domain preceding the PfSUB1
cleavage site as well as the generally more conserved C-
terminal domain [17,18]. A recent study of 89 PfMSP6
gene sequences from around the world identified 7 K1-
like and 11 3D7-like haplotypes [18].
Although a series of studies have now given a global
picture of PfMSP6 diversity, no study has assessed how
extensively PfMSP6 sequences can vary longitudinally at
a single study site. To fill this knowledge gap we analysed
samples collected between 2003 and 2006 as part of the
Malaria Immunology and Genetics in the Amazon
(MIGIA) longitudinal cohort study in Zungarococha, a
community of four villages located near Iquitos in the
Peruvian Amazon. Zungarococha is a hypoendemic
transmission environment, with a P. falciparum transmis-
sion rate of 0.13 infections/person/month during the
seven-month transmission season [19]. Consistent with
the hypoendemic transmission, P. falciparum infections
seem to routinely consist of few co-infecting genotypes,
but genetic diversity is still easily detectable at the popu-
lation level with at least five haplotypes defined for
PfMSP1  Block 2 in this community [20]. The MIGIA
project is therefore uniquely suited for vaccine candidate
studies, as it allows for the tracking of relatively geneti-
cally simple P. falciparum infections that are widely
spaced temporally but with considerable genetic diversity
at the population level. Furthermore, since samples are
collected as part of an ongoing longitudinal study, geno-
type data can be correlated with detailed clinical and epi-
demiological data. To further clarify the potential of
PfMSP6 as a vaccine candidate, PfMSP6 sequence diver-
sity was characterized in 506 P. falciparum samples col-
lected between 2003 and 2006 as part of the MIGIA
cohort, and the resulting genotypes were compared with
clinical and epidemiological data. The results inform the
rational assessment of PfMSP6 as a vaccine candidate.
Methods
Study site
A complete description of the MIGIA longitudinal cohort
study has been published previously [19]. In brief, the
study site consists of four villages that comprise the Zun-
garococha community: Zungarococha village, Puerto
Almendra, Ninarumi, and Llanchama. The community is
located in a stable hypoendemic malaria transmission
environment. Since 1994, both P. vivax and P. falciparum
have been transmitted during the annual seven-month
malaria season between January and July, with the pri-
mary vector being Anopheles darlingi [21]. Community
residents have equal access to healthcare in the commu-
nity health centre staffed by MIGIA cohort physicians,
live in similar housing conditions, and have similar
income levels. Travel outside of the community is rare, as
women typically work in or near their home and men
work in local agriculture or as fishermen along the nearby
Nanay River, a tributary of the Amazon River. Travel that
does occur is frequently to Iquitos, a city free of malaria
transmission.Neal et al. Malaria Journal 2010, 9:138
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Blood collection and DNA extraction
The sample collection process, involving both passive and
active case detection, has been detailed previously [19].
Briefly, passive case detection occurs when symptomatic
individuals seek care at the community health outpost,
where confirmation of malaria is made by microscopy. In
contrast, active case detection occurs through routine
community visits and identifies asymptomatic individu-
als. This study design increases the likelihood of sampling
both symptomatic and asymptomatic P. falciparum infec-
tions. All patients submit a 0.5 ml blood sample and,
upon malaria diagnosis are re-evaluated, submit another
blood sample, and are cleared of parasites by co-adminis-
tration of mefloquine and artesunate. Samples are sepa-
rated by centrifugation into serum and packed
erythrocyte fractions. Plasmodium  DNA is extracted
from the erythrocyte fraction using a Blood DNA kit
(Qiagen), and the species is identified by PCR using spe-
cies-specific primers. All samples are catalogued and
stored at -80°C until needed. For this study, P. falciparum
isolates collected between from 2003 to 2006 were
selected at random, excluding only subsequent infections
in the same individual that occurred within 60 days of the
initial infection in order to reduce the risk of duplication
due to parasite recrudescence.
Nested PCR and genotyping
The region of PfMSP6 where all detected inter- and intra-
allele genetic diversity has been shown to occur was
amplified using a nested PCR protocol with the external
primers 5'--CGTGAATACTATTTTCGTTACTT--3' and
5'--CAGCAGTCTTTTTTGTTTCAT--3' and the inter-
nal primers 5'--CCCCATCAATCTTATGTCCAG--3' and
5'--CACTTTCTTCATCTATGTCATCTTCTT--3'. The
amplified fragment corresponds to nucleotides 221-784
of the reference 3D7 PfMSP6 sequence, excluding primer
sequences. 1.0 μl of genomic DNA, extracted from P. fal-
ciparum-infected patients, was amplified using Choice-
Taq (Denville) in 35 cycles of 95°C for 30 seconds, 51.1°C
for 30 seconds, 65°C for 1 minute, and 65°C for 5 minutes.
For the nested PCR reaction, all conditions remained the
same except that 1 μl of the primary PCR reaction was
used as the template. Multiple negative controls were
included in each PCR experiment to monitor for contam-
ination. Allele-typing of PfMSP6  was performed using
ethidium bromide-stained agarose gel electrophoresis.
PfMSP6 amplified from the P. falciparum strains HB3 and
Dd2 were used as controls and run on all agarose gels to
aid classification of infections as either 3D7-like or K1-
like allele type. All PCR products were subsequently
sequenced using sequencing primer 5'--CTTCT-
TCATTTTCTTCTATCTC--3'. Sequence alignment was
performed using CodonCode Aligner 3.0.3 (CodonCode
Corporation).
Statistical analysis
Descriptive statistics, such as allele frequencies, percent-
ages, and means, were used to quantitatively summarize
all data sets. Comparisons between allele classes for age
group, sex, communities, symptom status, subsequent
allele, subsequent P. falciparum infections, year of infec-
tion, time to next P. falciparum infection, and compari-
sons between all other variables of interest were
performed using Pearson chi-square or Fisher's exact chi-
square, when necessary. Infections were classified as
symptomatic if patients experienced febrile illness at least
two days prior to diagnosis, had a detected fever ≥ 38.3°C,
and/or had a packed cell haematocrit < 30%. Compari-
sons between means of actual age and days to next P. fal-
ciparum infection were performed using the independent
t-test. All statistical tests were two-tailed and performed
using a 5% significance level in JMP (version 8.0.1.0; SAS
Institute, Inc., Cary, NC).
Ethical approval
This study was approved by the Institutional Review
Boards of the University of Alabama at Birmingham, New
York University and the Peruvian Ministerio de Salud,
Instituto Naccional de Salud. All participants in the study
gave informed consent in writing prior to enrollment in
the study.
Results
Significant variation in PfMSP6 allele frequency is observed 
across transmission seasons
506 samples were selected from P. falciparum infections
detected in the MIGIA cohort over the 2003-2006 trans-
mission seasons. Infections that occurred in a given indi-
vidual within 60 days of a prior infection were excluded.
This, combined with the fact that all patients were treated
upon detection of a P. falciparum infection (see Meth-
ods), significantly reduces the likelihood that any given
infection was represented more than once in the sample
set.
Nested PCR was used to amplify nucleotides 221-784
of PfMSP6 from each sample (nucleotide position taken
from the reference 3D7 PfMSP6 sequence; Figure 1), a
fragment that includes both the known dimorphic
regions as well as previously identified SNPs both before
and after the PfSUB1 cleavage site [17]. Samples were
allele-typed by agarose gel electrophoresis; of the 506
samples genotyped, 463 contained the 3D7 PfMSP6
allele-class (91.5%) and 43 contained the K1 allele-class
(8.5%). This supports previous reports that 3D7-like
alleles are more prevalent world-wide (73.8% of published
PfMSP6 sequences, [18]). No mixed infections of K1- and
3D7-class alleles were detected. The observed allele fre-
quency varied across the transmission seasons, with the
frequency of K1-class infections decreasing from 21.5% inNeal et al. Malaria Journal 2010, 9:138
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Figure 2 PfMSP6 allele distribution changes significantly over consecutive transmission seasons. Distribution of the K1- and 3D7-like allele fre-
quencies across the 2003-2006 transmission seasons showed a significant decline in K1-allele frequency between 2003/2004 and 2005/2006. Each bar 
represents the percentage of each allele type detected in n samples for the given year, and * denotes significant differences between paired years 
with p = 0.0001 in χ2 analysis.
Figure 1 Genotyping PfMSP6 using nested PCR and agarose gel electrophoresis. This study utilizes a nested PCR protocol to amplify the region 
of PfMSP6 where most inter- and intra-allele genetic diversity has been shown to occur. The two major PfMSP6 allele types, K1-class and 3D7-class al-
leles, result in nested PCR products of significantly different sizes, and allele genotyping was scored using agarose gel electrophoresis, as shown.Neal et al. Malaria Journal 2010, 9:138
http://www.malariajournal.com/content/9/1/138
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2004 to 1.0% in 2006, and with allele frequencies in 2003
and 2004 statistically significantly different to those in
2005 and 2006 (Figure 2).
Correlation of PfMSP6 allele frequencies with 
epidemiological and clinical data
The MIGIA cohort study results in the collection of wide-
ranging epidemiological and clinical data [19]. PfMSP6
allele frequency was compared with this data, in order to
establish whether certain alleles associated with specific
epidemiological features. While there were no significant
associations between PfMSP6 allele frequency and age or
gender, there was a significant association between
PfMSP6 allele frequency and community (Table 1). The
Zungarococha community consists of four independent
villages (map shown in Figure 3), and P. falciparum infec-
tion burden is not uniform across the villages: Zungaro-
cocha village, the largest in the community, carries the
smallest burden of infection. Village location data was
available for 503 samples (Figure 3); comparing allele fre-
q u e n c i e s  w i t h  l o c a t i o n  r e v e a l e d  t h a t  P u e r t o  A l m e n d r a
had a significant increase in K1-class infections (> 2-fold,
p = 0.0061) compared to the other villages, while Llan-
chama had a significant decrease in K1-class infections (>
14-fold, p = 0.0007) compared to the other villages (Table
2).
Comparison with clinical data revealed no association
between PfMSP6 allele class and symptom status (Table
1). The longitudinal nature of the MIGIA cohort study,
where individuals are followed over a long period of time,
also allows the analysis of subsequent infections in the
same individuals spaced by at least 60 days. Of the 506
infections genotyped, 79 infections were identified as
successive infection pairs, where individuals had two dis-
tinct P. falciparum infections within < 500 days. Of these
79 infections, 65 were successfully genotyped and 53 had
comparable clinical symptom data. No statistically signif-
icant associations between subsequent allele, subsequent
P. falciparum infection, or time to next infection were
detected (Table 3). If allele-specific immunity exists
against PfMSP6, then a subsequent infection might be
expected to be of a different allele-class than the original
infection. Comparing the allele types present in the initial
and subsequent infections yielded no significant depar-
tures from the average allele frequencies, but this analysis
is not powered to detect significant associations because
of the low number of K1 infections at the study site, such
that of the individuals with successive infection pairs,
only one had a K1-class infection at their initial visit, and
only one individual had a K1-class infection during the
subsequent infection.
Table 1: Association of PfMSP6 allele type with MIGIA cohort study epidemiological data.
Factor 3D7-Class K1-Class P-value
Age Group 0.7530
< 15 years 148 15
≥ 15 years 307 28
Gender 0.7276
Male 250 24
Female 210 18
Community 0.0008*
Zungarococha 70 4
Puerto Almendra 92 16
Ninarumi 181 21
Llanchama 118 1
Symptom Status 0.3757
Asymptomatic 118 12
Symptomatic 327 24
Using χ2 analysis, relationships between PfMSP6 allele class and various epidemiological factors were assessed; statistically significant 
associations are indicated with an asterisk. There was a significant association between the infecting allele type and the village at which the 
P. falciparum samples were collected.Neal et al. Malaria Journal 2010, 9:138
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Page 6 of 10
Figure 3 Distribution of P. falciparum samples analysed. Zungarococha is a small community in the Peruvian Amazon near Iquitos consisting of 
four separate villages of varying size: Zungarococha village (population = 805), Puerto Almendra (population = 272), Ninarumi (population = 590), and 
Llanchama (population = 203). Since 2003, the MIGIA cohort study has monitored P. falciparum transmission throughout the community using both 
active and passive sample detection (for details, see Methods section). Samples were collected from all four villages; the number genotyped from each 
village reflects variation in both the size of the villages and the burden of P. falciparum infection.Neal et al. Malaria Journal 2010, 9:138
http://www.malariajournal.com/content/9/1/138
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Sequence variation in PfMSP6 is limited
To investigate intra-allele sequence diversity, all 506 sam-
ples were sequenced and compared to published
sequences. Any samples that showed potential SNPs were
re-amplified and re-sequenced to eliminate the possibility
of PCR-induced error. All 3D7-class PfMSP6 alleles were
identical to the HB3 strain [GenBank:AY518889], and all
K1-class alleles were identical to the K1 strain [Gen-
Bank:AY518890]; there was no sequence level diversity
across all four transmission seasons.
This sequence stability is in contrast to the adjacent
gene on chromosome 10, PfMSP3, which also encodes a
related merozoite surface antigen that is under active
development as a vaccine candidate [10-12]. Although
PfMSP3 sequence diversity at this study site was also lim-
ited, previous studies at the same site did reveal rare
PfMSP3 sequence variation, all of which shared the same
single SNP [22]. Of the 506 samples genotyped for
PfMSP6 in this study, 10 had previously been shown to
have PfMSP3 SNPs; none of these 10 samples contained
PfMSP6 sequence variants.
Comparison of PfMSP3  and  PfMSP6  gentoypes
revealed some evidence of recombination between these
two adjacent genes. PfMSP3 also consists of two defined
allele classes, 3D7-like and K1-like [23,24]. The majority
of samples genotyped in both studies contained either
both 3D7-class PfMSP3 and 3D7-class PfMSP6 alleles, or
K1-class PfMSP3 and K1-class PfMSP6 alleles. Only five
samples had mixed PfMSP3 and PfMSP6 alleles, in keep-
ing with established low P. falciparum recombination
rates in South America [25]: three infections where a K1-
class PfMSP6 allele was paired with a 3D7-class PfMSP3
allele, and two infections where a 3D7-class PfMSP6 allele
was paired with a K1-class PfMSP3 allele.
Discussion
Recent discussions of global malaria elimination as a
stated goal for the research community have increased
the focus on the decades-long hunt for an effective P. fal-
ciparum  vaccine [26]. While it is sometimes debated
whether a vaccine is a necessary constituent of such cam-
paigns, or precisely which stage should be targeted [27],
the possible emergence of P. falciparum strains resistant
to artemisinin, the current front-line drug in global
malaria treatment campaigns [28], emphasizes that it may
be premature to reject any approach if the global effort
against malaria is to be successful.
While a vaccine targeting a sporozoite stage antigen is
currently undergoing Phase III trials [1], vaccines target-
ing asexual stage antigens, which in theory would have
the clinical advantage of limiting symptoms even if they
were not completely effective in eliminating parasites,
have lagged somewhat in development. Genetic diversity
is clearly a major hurdle for many asexual antigen vac-
cines [14], and is presumably responsible for the disap-
pointing results from recent field trials of a PfMSP1-
Table 2: Association of PfMSP6 allele type with village of residence.
Village 3D7-Class K1-Class P-value
Zungarococha 0.3215
ZG 70 4
Others 391 38
Puerto Almendra 0.0061*
PA 92 16
Others 369 26
Ninarumi 0.1742
NR 181 21
Others 280 21
Llanchama 0.0007*
LL 118 1
Others 343 41
Using χ2 analysis, relationships between infecting PfMSP6 allele and village of residence were assessed; statistically significant associations 
are indicated with an asterisk. Puerto Almendra showed a statistically significant increase in K1 infections (>2-fold) compared to other 
villages. Llanchama showed a statistically significant decrease in K1 infections (>14-fold) compared to other villages.Neal et al. Malaria Journal 2010, 9:138
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based vaccine [29]. To avoid similar disappointment in
the future, it is essential that all potential vaccine candi-
dates undergo rigorous go/no-go analysis in the pre-clini-
cal phase, with candidates being eliminated from
consideration if they do not meet certain criteria. Several
approaches can be used to inform these go/no-go deci-
sions, including experimental genetic manipulation and
detailed field studies investigating both natural genetic
diversity and immunoepidemiology.
PfMSP6 is a merozoite candidate antigen at an early
stage of pre-clinical development, lacking significant field
data that supports its potential role as a viable vaccine
candidate. To help inform go/no-go decisions for
PfMSP6-based vaccine development, PfMSP6  diversity
was followed over multiple transmission seasons in a
hypoendemic transmission environment in Peru. At a
sequence level, PfMSP6 diversity was very limited in this
setting. No intra-allele sequence variants were found in
over 500 distinct P. falciparum infections spanning four
transmission seasons at the MIGIA cohort study site near
Iquitos, Peru. While P. falciparum genetic diversity is, in
general, much lower in South America than other regions
[25], SNPs were detected in two other vaccine antigens,
PfMSP119 and PfMSP3, at the same site over the same
period [20,22]. Genetic stability in low transmission is a
generally low bar for vaccine candidate antigens, but the
relative stability of the PfMSP6 gene compared to other
vaccine antigens even in this setting certainly supports its
further investigation as a vaccine candidate.
However, although PfMSP6 was stable at a sequence
level, the frequency of the two PfMSP6 allele classes fluc-
tuated significantly between transmission seasons and
between villages within the study site. K1 allele-class
infections, which are in the minority at this study site just
as they appear to be globally [18], exhibited an overall
downward trend over the study period, from 13.2% of
total infections in 2003 to 1.0% of total infections in 2006,
with a statistically significant drop-off in infections
between 2003/2004 and 2005/2006. Within the Zungaro-
cocha community, K1-class infections were over-repre-
s e n t e d  i n  P u e r t o  A l m e n d r a  ( p  = 0.0061) and under-
represented in Llanchama (p = 0.0007), despite the fact
that the two villages are less than 3 km apart. Population
differences between the two villages provide a potential
explanation. Puerto Almendra is a heavy-traffic village on
the Nanay River, and the associated activities of non-resi-
dents and position on the riverbank may increase the
likelihood of introduction of new allele types through
infectious travellers or transport of infected mosquitoes
from upstream transmission. Llanchama, by contrast, is
the smallest and most isolated village in the community,
with little exposure to outside infections.
In addition to measuring PfMSP6 allele-class diversity
at the community level, clinical and epidemiological data
collected as part of the MIGIA cohort study allowed for
the assessment of specific PfMSP6 allele classes with clin-
ical data, which revealed no association of allele class
with any clinical data or with any other epidemiological
data. The extensive longitudinal data collected as part of
the MIGIA study also allowed testing for evidence of
allele-specific immunity by assessing whether either
infecting allele-class correlated with an increased fre-
quency of subsequent infections, the length of time until
subsequent infection, the allele-class of subsequent infec-
tions, or an increased frequency of asymptomatic subse-
quent infections. No significant associations were
Table 3: Association of PfMSP6 allele with subsequent infection data.
3D7-Class K1-Class P-value
Subsequent Allele 0.3432
3D7-Class 55 6
K1-Class 3 1
Subsequent Pf Infection 0.5720
No 392 35
Yes 71 8
Next Infection (days) 0.6503
Mean 318 276
n6 1 4
Using χ2 analysis, relationships between initial PfMSP6 infection with subsequent P. falciparum infection and subsequent PfMSP6 allele type 
were assessed. Time between initial and subsequent infections was assessed using a t-test; no statistically significant associations were 
detected.Neal et al. Malaria Journal 2010, 9:138
http://www.malariajournal.com/content/9/1/138
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observed, but the possibility of allele-specific host
immune responses should not be excluded due to the lack
of statistical power from the infrequent number of infec-
tions characteristic of a hypoendemic environment, and
the low incidence of K1-class infections in particular.
While the absence of intra-allele class sequence varia-
tion in PfMSP6 is a positive attribute for any vaccine can-
didate, the dynamism of PfMSP6 allele frequencies even
in a hypoendemic transmission environment such as the
one in the MIGIA cohort emphasizes the fact that any
PfMSP6-based vaccine must be able to provide protec-
tion against both allele classes. This could be achieved by
using a fragment that is conserved between both alleles,
or a fragment that is not conserved but is able to induce
cross-protection, or by mixing antigens from both allele
classes. The simplest way to distinguish between the via-
bility of these approaches it to use immunoepidemiology
studies to establish which domains of PfMSP6 are immu-
nogenic in natural P. falciparum infections, and whether
the antibodies raised against them are able to cross-react
between allele classes.
Conclusions
PfMSP6 is a P. falciparum asexual vaccine candidate with
limited pre-clinical data to support its advancement or
elimination from further development. Data from P. falci-
parum  infections in the Peruvian Amazon establishes
that it is significantly less genetically variable than other
merozoite surface vaccine candidate antigens at this site,
but PfMSP6 allele frequencies can vary significantly both
over time and between local villages. The design of any
future PfMSP6-based vaccine must take this data into
account and provide protection against both allele classes
if it is to warrant further development.
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